Clinical and experimental studies of multiple sclerosis in Russia: experience of the leading national research centers

References

• Kesserling J, Comi G, Thompson AJ, editors. Multiple Sclerosis: Recovery of Function and Neurorehabilitation. Cambridge University Press, New York; 2010.
   Google Scholar
• Filippi M, Rocca MA. Cortical reorganisation in patients with MS. J Neurol Neurosurg Psychiatry. 2004;75(8):1087–1089.15258204
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA. Functional MR imaging in multiple sclerosis. Neuroimag Clin N Am. 2009;19(1):59–70.
   Web of Science ®Google Scholar
• Rocca MA, Colombo B, Falini A, et al Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol. 2005;4(10):618–626.16168930
   PubMed Web of Science ®Google Scholar
• Kulikova SN, Peresedova AV, Krotenkova MV, Bryukhov VV, Trifonova OV, Zavalishin IA. Dynamic study of reorganisation of the cortex and the structure of the conduction pathways in patients with relapsing-remitting multiple sclerosis and hand paralysis. Annaly klinicheskoi i eksperimentalnoi nevrologii. 2014;8(1):22–29.
   Google Scholar
• Donaldson DI, Buckner RL. Effective paradigm design In: Jezzard P, Matthews PM, Smith SM, editors. Functional MRI, an Introduction to Methods. Oxford: Oxford University Press; 2003: 177–197.
   Google Scholar
• Mancini L, Ciccarelli O, Manfredonia F, et al Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis. Neuroimage. 2009;45(2):500–511.19135155
   PubMed Web of Science ®Google Scholar
• Freedman MS, Selchen D, Arnold DL, et al Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013;40(3):307–323.23603165
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903–914.18789766
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B, et al 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889–897.19729344
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Camesasca F, et al Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011;76(14):1222–1228.21464426
   PubMed Web of Science ®Google Scholar
• Arnon R, Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm. 2009;116(11):1443–1449.19669693
   PubMed Web of Science ®Google Scholar
• Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol. 2013;260(7): 1901–1906.23589190
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Hartung HP. Interferon-beta and neuroprotection in multiple sclerosis-facts, hopes and phantasies. Exp Neurol. 2007;203(1): 1–4.17069803
   PubMed Web of Science ®Google Scholar
• Leray E, Yaouang J, Le Page E, et al Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(Pt7):1900–1913.20423930
   PubMed Web of Science ®Google Scholar
• Gabibov AG, Belogurov AA Jr, Lomakin YA, et al Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen. FASEB J. 2011;25(12):4211–4221. doi: 10.1096/fj.11-190769 Epub August 22, 2011.21859892
   PubMed Web of Science ®Google Scholar
• Owens GP, Bennett JL. Trigger, pathogen, or bystander: the complex nexus linking Epstein-Barr virus and multiple sclerosis. Mult Scler. 2012;18(9):1204–1208.22685062
   PubMed Web of Science ®Google Scholar
• Cross AH, Naismith RT. Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med. 2014;275(4):350–363. doi: 10.1111/joim.12203 Epub March 11, 2014.24444048
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev. 1993;6(4):382–427.8269393
   PubMed Web of Science ®Google Scholar
• Levin LI, Munger KL, O’Reilly EJ, et al Primary infection with the Epstein-Barr virus and the risk of multiple sclerosis. Ann Neurol. 2010;67:824–830.33.20517945
   PubMed Web of Science ®Google Scholar
• Pender MP. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev. 2009;8:563–568.19254880
   PubMed Web of Science ®Google Scholar
• Reindl MP, Kuenz BB, Berger T. B cells and antibodies in MS results. Probl Cell Differ. 2010;51:99–113.
   Google Scholar
• Hikada M, Zouali M. Multistoried roles for B lymphocytes in autoimmunity. Nat Immunol. 2010;11:1065–1068.21079626
   PubMedGoogle Scholar
• Kabat EA, Glusman M, Knaub V. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med. 4: 653–662.18856761
   PubMed Web of Science ®Google Scholar
• Chamczuk AJ, Ursell M, O’Connor P, Jackowski G, Moscarello MA. A rapid ELISA-based serum assay for myelin basic protein in multiple sclerosis. J Immunol Methods. 2002;262:21–27.11983216
   PubMed Web of Science ®Google Scholar
• Ponomarenko NA, Durova OM, Vorobiev II, et al Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol Lett. 2006;103(1):45–50. 10.1016/j.imlet.2005.10.006.16297986
   PubMed Web of Science ®Google Scholar
• Berger T, Rubner P, Schautzer F, et al Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349(2):139–145. 10.1056/NEJMoa022328.12853586
   PubMed Web of Science ®Google Scholar
• Lomakin YA, Zakharova MY, Stepanov AV, et al Heavy-light chain interrelations of MS-associated immunoglobulins probed by deep sequencing and rational variation. Mol Immunol. 2014;62(2):305–314. 10.1016/j.molimm.2014.01.013.24534716
   PubMed Web of Science ®Google Scholar
• Gabibov AG, Ponomarenko NA, Tretyak EB, Paltsev MA, Suchkov SV. Catalytic autoantibodies in clinical autoimmunity and modern medicine. Autoimmun Rev. 2006;5(5):324–330. Epub February 28, 2006.16782557
   PubMed Web of Science ®Google Scholar
• Durova OM, Vorobiev II, Smirnov IV, et al Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. Mol Immunol. 2009;47(1):87–95. doi:10.1016/j.19201029
   Web of Science ®Google Scholar
• Mahendra A, Sharma M, Rao DN, et al Antibody-mediated catalysis: induction and therapeutic relevance. Autoimmun Rev. 2013;12(6):648–652. doi:10.1016/j.autrev.2012.10.009.23207286
   Web of Science ®Google Scholar
• Doronin VB, Parkhomenko TA, Castellazzi M, et al Comparison of antibodies hydrolyzing myelin basic protein from the cerebrospinal fluid and serum of patients with multiple sclerosis. PLoS One. 2014;9(9):e107807.25265393
   PubMed Web of Science ®Google Scholar
• Planque SA, Nishiyama Y, Hara M, et al Physiological IgM class catalytic antibodies selective for transthyretin amyloid. J Biol Chem. 20149;289(19):13243–13258. 10.1074/jbc.M114.557231 Epub March 19, 2014.24648510
   PubMed Web of Science ®Google Scholar
• Belogurov A Jr, Kozyr A, Ponomarenko N, Gabibov A. Catalytic antibodies: balancing between Dr Jekyll and Mr Hyde. Bioessays. 2009;31(11):1161–1171.19795406
   PubMed Web of Science ®Google Scholar
• Ponomarenko NA, Durova OM, Vorobiev II, et al Catalytic antibodies in clinical and experimental pathology: human and mouse models. J Immunol Methods. 2002;269(1–2):197–211.12379362
   PubMed Web of Science ®Google Scholar
• Ponomarenko NA, Durova OM, Vorobiev II, et al Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A. 2006;103(2):281–286. Epub December 30, 2005.16387849
   PubMed Web of Science ®Google Scholar
• Belogurov AA Jr, Kurkova IN, Friboulet A, et al Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol. 2008;180(2): 1258–1267.18178866
   PubMed Web of Science ®Google Scholar
• Nastasijevic B, Wright BR, Smestad J, Warrington AE, Rodriguez M, Maher LJ 3rd. Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis. PLoS One. 2012;7(6):e39595 10.1371/journal.pone.0039595.22761835
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II- defined cohort of patients with progressive multiple sclerosis: results of a 24-month double- blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol. 2006;13(8):887–895.16879301
   PubMed Web of Science ®Google Scholar
• Fontoura P, Garren H. Multiple sclerosis therapies: molecular mechanisms and future Results Probl Cell Differ. 2010;51:259–285.
   Google Scholar
• Belogurov AA Jr, Zargarova TA, Turobov VI, et al Suppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46–62. Autoimmunity. 2009;42(4):362–364.19811302
   PubMed Web of Science ®Google Scholar
• Belogurov AA Jr, Stepanov AV, Smirnov IV, et al Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J. 2013;27(1):222–231. 10.1096/fj.12-213975 Epub October 9, 2012.23047895
   PubMed Web of Science ®Google Scholar
• Basler M, Mundt S, Muchamuel T, et al Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med. 2014;6(2):226–238. 10.1002/emmm.201303543.24399752
   PubMed Web of Science ®Google Scholar
• Wehenkel M, Ban J-O, Ho Y-K, Carmony KC, Hong JT, Kim KB. A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer. 2012;107(1):53–62. 10.1038/bjc.2012.243.22677907
   PubMed Web of Science ®Google Scholar
• Belogurov A Jr, Kuzina E, Kudriaeva A, et al Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB J. 2015;29(5):1901–1913.25634956
   PubMed Web of Science ®Google Scholar
• Kravtsova-Ivantsiv Y, Ciechanover A. Non-canonical ubiquitin-based signals for proteasomal degradation. J Cell Sci. 2012;125(3):539–548. 10.1242/jcs.093567.22389393
   PubMed Web of Science ®Google Scholar
• Belogurov A Jr, Kudriaeva A, Kuzina E, et al Multiple sclerosis autoantigen myelin basic protein escapes control by ubiquitination during proteasomal degradation. J Biol Chem. 2014;289(25):17758–17766. 10.1074/jbc.M113.544247 Epub April 16, 2014.24739384
   PubMed Web of Science ®Google Scholar
• Kuzina E, Kudriaeva A, Smirnov I, Dubina MV, Gabibov A, Belogurov A Jr. Glatiramer acetate and nanny proteins restrict access of the multiple sclerosis autoantigen myelin basic protein to the 26s proteasome. Biomed Res Int. 2014;2014:926394 10.1155/2014/926394 Epub September 8, 2014.25276831
   PubMed Web of Science ®Google Scholar
• Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14599–14606. 10.1073/pnas.0404874101.15306684
   PubMed Web of Science ®Google Scholar
• Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011;18(1):21–29.20537877
   PubMedGoogle Scholar
• Glinka EM, Edelweiss EF, Sapozhnikov AM, et al A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells. Gene. 2006;366(1):97–103.16300908
   PubMed Web of Science ®Google Scholar
• Deyev SM, Lebedenko EN. Modern technologies for creating synthetic antibodies for clinical application. Acta Naturae. 2009;1(1):32–50.22649585
   PubMed Web of Science ®Google Scholar
• Balandin TG, Edelweiss E, Andronova NV, et al Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts Invest New Drugs. 2011;29(1): 22–32.19789841
   PubMed Web of Science ®Google Scholar
• Stepanov AV, Belogurov AA Jr, Ponomarenko NA, et al Design of targeted B cell killing agents. PLoS One. 2011;6(6):e20991 10.1371/journal.pone.0020991 Epub June 6, 2011.21677771
   PubMed Web of Science ®Google Scholar
• Aleksandar D, Bharath W, Laurie Z, Moses R. Deletion of virus-specific T-cells enhances remyelination in a model of multiple sclerosis. J Neurol Transl Neurosci. 2014;2(1):1032.25383388
   PubMedGoogle Scholar